ImmunoGen 将来の成長

Future 基準チェック /66

ImmunoGen利益と収益がそれぞれ年間45.2%と26%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に33.2% 44.6%なると予測されています。

主要情報

45.2%

収益成長率

44.6%

EPS成長率

Biotechs 収益成長	0%
収益成長率	26.0%
将来の株主資本利益率	33.2%
アナリストカバレッジ	Good
最終更新日	12 Feb 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BMV:IMGN * - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,026	389	280	341	7
12/31/2025	784	289	350	313	10
12/31/2024	541	109	175	148	10
12/31/2023	377	24	0	5	9
9/30/2023	288	-74	-200	-198	N/A
6/30/2023	190	-180	-266	-265	N/A
3/31/2023	121	-240	-263	-262	N/A
12/31/2022	109	-223	-231	-230	N/A
9/30/2022	96	-201	-217	-215	N/A
6/30/2022	89	-161	-187	-186	N/A
3/31/2022	92	-129	-167	-166	N/A
12/31/2021	70	-139	-171	-169	N/A
9/30/2021	128	-71	-116	-115	N/A
6/30/2021	137	-56	-112	-111	N/A
3/31/2021	135	-49	-97	-95	N/A
12/31/2020	132	-44	-80	-79	N/A
9/30/2020	91	-71	-121	-120	N/A
6/30/2020	86	-70	-125	-124	N/A
3/31/2020	87	-89	-128	-127	N/A
12/31/2019	82	-104	-91	-88	N/A
9/30/2019	51	-151	-101	-97	N/A
6/30/2019	48	-176	-107	-102	N/A
3/31/2019	42	-174	-113	-106	N/A
12/31/2018	53	-169	-172	-166	N/A
9/30/2018	79	-140	-159	-155	N/A
6/30/2018	77	-150	-71	-69	N/A
3/31/2018	107	-117	-11	-9	N/A
12/31/2017	115	-96	7	8	N/A
9/30/2017	90	-117	0	1	N/A
6/30/2017	89	-105	N/A	-93	N/A
3/31/2017	57	-142	N/A	-150	N/A
12/31/2016	49	-157	N/A	-143	N/A
9/30/2016	53	-156	N/A	-141	N/A
6/30/2016	60	-145	N/A	-124	N/A
3/31/2016	65	-129	N/A	-120	N/A
12/31/2015	57	-119	N/A	-86	N/A
9/30/2015	87	-72	N/A	-68	N/A
6/30/2015	86	-61	N/A	-55	N/A
3/31/2015	79	-57	N/A	-46	N/A
12/31/2014	74	-73	N/A	-66	N/A
9/30/2014	56	-82	N/A	-49	N/A
6/30/2014	60	-71	N/A	-54	N/A
3/31/2014	58	-67	N/A	-46	N/A
12/31/2013	76	-31	N/A	-39	N/A
9/30/2013	49	-59	N/A	-63	N/A
6/30/2013	36	-73	N/A	-60	N/A
3/31/2013	35	-73	N/A	-65	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IMGN *は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 7.7% ) よりも高い成長率であると考えられます。

収益対市場: IMGN *今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: IMGN *今後 3 年以内に収益を上げることが予想されます。

収益対市場: IMGN *の収益 ( 26% ) MX市場 ( 7.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: IMGN *の収益 ( 26% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IMGN *の自己資本利益率は、3年後には高くなると予測されています ( 33.2 %)

ImmunoGen 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2023

Forecast breakeven date moved forward to 2023

Forecast breakeven date moved forward to 2024

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

Forecast to breakeven in 2025

No longer forecast to breakeven

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Forecast to breakeven in 2023

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Forecast breakeven date moved forward to 2023

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Forecast breakeven date moved forward to 2024

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Forecast to breakeven in 2025

No longer forecast to breakeven

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Forecast to breakeven in 2025

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘